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Abstract
Objective – To evaluate various surrogate markers associated with the inflammatory and counter-
inflammatory responses with respect to mortality in dogs with systemic inflammatory response syndrome
(SIRS).
Design – Prospective observational study.
Setting – Veterinary Teaching Hospital.
Animals – Twenty-eight dogs with naturally occurring diseases and SIRS from January 2007 to May 2009.
Interventions – Upon admission to the veterinary hospital, history and baseline data from the physical
examination, including parameters previously defined for meeting SIRS criteria, were documented.
Heparinized blood samples were collected and plasma cytokines interleukin-6 (IL-6), IL-10, and high-
mobility group box 1 (HMGB1) were measured by sandwich ELISA.
Measurements and Main Results – In nonsurvivors, median plasma HMGB1 concentrations (0.718 mg/L,
interquartile range [IQR]; 0.300–1.626 mg/L) and the ratio of HMGB1 to IL-10 (2.236, IQR; 0.972–5.367) were
significantly increased as compared with those found in survivors (0.300 mg/L, IQR; 0.300–0.312 mg/L for
HMGB1; 1.017, IQR; 0.862–1.126 for the ratio of HMGB1 to IL-10, P 5 0.007 and 0.024, respectively). Plasma
IL-6, IL-10, and the ratio of IL-6 to IL-10 were not significantly different between groups. Among the
parameters studied, HMGB1 and the ratio of HMGB1 to IL-10 performed the best in discriminating outcome
in dogs with SIRS according to receiver operator characteristic curve analysis.
Conclusions – Increases in plasma HMGB1 concentration and the ratio of HMGB1 to IL-10 may predict poorer
outcomes in dogs with SIRS. The approach described may lead to reliable prognostic biomarkers and new
therapeutic concepts in the study of SIRS in dogs.
(J Vet Emerg Crit Care 2010; 20(3): 298–302) doi: 10.1111/j.1476-4431.2010.00539.x
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Introduction
Systemic inflammatory response syndrome (SIRS) is a
massive and global immune response to challenges of
infectious or noninfectious origin.1 The pathophysiology
of SIRS is complex and numerous factors within the
host’s immune system interact to determine outcome.2
Evidence suggests that endogenous cytokines have a
major role in SIRS pathogenesis and that overstimula-
tion of cytokine production contributes to poor out-
comes.3–7 However, further evidence suggests that
SIRS outcome is not simply the consequence of exces-
sive proinflammatory cytokine production, but rather
an imbalance of pro- and anti-inflammatory mediators,
suggesting a failure of inherent, protective mechanisms.
Further knowledge of the factors influencing outcome
in SIRS may lead to new diagnostic techniques and
therapies for this life-threatening condition.8 Thus,
identification of biomarkers that could quantify disease
severity and predict patient prognosis would be
beneficial in both research studies and clinical applica-
tions.
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Animal models and a human cohort study support
the use of several markers of SIRS, including interleu-
kin-1 (IL-1), tumor necrosis factor-a, IL-6, IL-10,
C-reactive protein and lipopolysaccharide-binding pro-
tein to predict mortality in patients with SIRS.9–11 In
addition, ratios of proinflammatory to anti-inflamma-
tory cytokines have been examined as prognostic
indicators.12 Recent studies have suggested that high-
mobility group box 1 (HMGB1), a DNA-binding intra-
nuclear protein, is a late activator of the inflammatory
cascade that is released from necrotic cells into the ex-
tracellular milieu.13–15 It acts as a damage-associated
molecular pattern or alarmin, stimulating the release of
numerous proinflammatory cytokines by human mono-
cytes.15 HMGB1 levels correlate with hospital mortality
and also with the organ failure scores in human septic
patients.13,16,17
In clinical veterinary medicine, a few studies have
attempted to identify prognostic markers of SIRS in
dogs.18–21 Otto et al21 reported that an increase in
plasma tumor necrosis factor-a activity was predictive
of mortality in naturally occurring parvoviral enteritis.
In another report, plasma IL-6 levels correlated with
disease severity and mortality in canine SIRS and sep-
sis.3 Although measurement of HMBG1 concentration
has shown promise in humans and laboratory animals,
to our knowledge, HMGB1 has not been investigated as
a biomarker in naturally occurring SIRS in dogs.
The purpose of the present study was to examine
HMGB1 as well as IL-6 as prognostic surrogate markers
for mortality in dogs with SIRS. In addition, because
outcome in dogs with SIRS may be associated with im-
balances of pro- and anti-inflammatory cytokines, we
also evaluated the ratios of HMGB1 to IL-10 and IL-6 to
IL-10.
Materials and Methods
This was a prospective, observational study of dogs
with SIRS. Eligible subjects were derived from the
entire canine population hospitalized by one service of
the Department of Internal Medicine from January 2007
to May 2009. Diagnostic criteria for SIRS were based
on the study by de Laforcade et al22 and a diagnosis
of SIRS required 2 or more of the following: hypo- or
hyperthermia (o37.81C or 439.41C), tachycardia (heart
rate 4140/min), tachypnea (respiratory rate 420/min),
leukocytosis (416  109 cells/L [416  103 cells/mL]) or
leukopenia (o6109 cells/L [o6103 cells/mL]) or 43%
band forms in the WBC count. The present study was
inclusive of infectious and noninfectious causes of SIRS.
Before enrollment in this study, informed consent
was obtained from each owner. All aspects of this study
were approved by the Committee on Bioethics at our
institution.
Details regarding patient history, onset of clinical
signs, and baseline data from the physical examination
were recorded. Blood was immediately collected by
venipuncture into heparin-containing tubes and the
separated plasma was stored at  801C until analysis.
Mortality was defined as death or euthanasia due to
poor prognosis. Survival was defined as discharge from
the hospital.
Laboratory assays
Plasma IL-6 and IL-10 were measured by sandwich
ELISA based on commercially available matched ca-
nine antibody pairs.a Because the molecular structure
of canine HMGB1 is identical to that of the human
molecule,23 a sandwich ELISA for human HMGB1b was
used for the quantitative determination of canine
HMGB1 concentrations in plasma. Absorbances were
measured at A450–A540 with a microplate spectropho-
tometerc and sample concentrations were calculatedd
from standard curves of the commercially available pro-
teins. The lower limits of assay detection were 0.063mg/
L (0.063 ng/mL) for IL-6, 0.031mg/L (0.031 ng/mL) for
IL-10, and 0.300mg/L (0.300 ng/mL) for HMGB1. Values
below the detection limit of the assay were assigned the
default values of 0.063 (IL-6), 0.031 (IL-10), and 0.300
(HMGB1)mg/L (ng/mL) for statistical analysis. Sample
assays were performed in duplicate. For negative con-
trols, cytokine concentrations were measured in 12 clin-
ically healthy beagles (1–2 years of age).
Statistical analysis
Data are presented as the median and interquartile
range (IQR) or as the mean (SD). A Shapiro-Wilk test
was used to verify normality of the data.e Cytokine
concentrations in survivors and nonsurvivors were
compared by Mann-Whitney U-test. A two-tailed
P-value o0.05 was considered statistically significant.
Receiver operator characteristic curves and the area
under the curve were also calculated for the prognostic
markers evaluated. Ninety-five percent confidence
intervals (CIs) were reported for the area under the
curve.
Results
During the study period, 142 client-owned dogs were
considered for inclusion in the study. Twenty-eight
dogs of 13 different breeds met inclusion criteria and
were enrolled. Twelve of 28 (43%) dogs were male, 2 of
12 were castrated, and 16 of 28 (57%) were female, 3 of
16 were spayed. The dogs had a median age of 5 years
(range, 2 mo to 14 y). Dogs included in study had the
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following diagnoses: trauma (eg, bite wounds or motor
vehicle accident; n 5 4), pyometra (n 5 3), canine par-
voviral enteritis (n 5 3), heart failure (n 5 2), peritonitis
from gastrointestinal tract perforation (n 5 2), and 1 of
each of the following, canine distemper virus infection,
bacterial glomerulonephritis, acute hepatitis, pulmo-
nary thromboembolism, gastroenteritis sequel to for-
eign body ingestion, fever of unknown origin, bacterial
mastitis, acute pancreatitis, Cushing’s syndrome, severe
hemorrhage, immune-mediated hemolytic anemia, rec-
tal prolapse, ethylene glycol toxicosis, and bacterial
pyoderma. The mean (SD) for body temperature, pulse
rate, respiration rate, and WBC counts were 39.31C
(1.11C), 143/min (22/min), 43/min (11/min), and
19.1  109 cells/L (13.9  109 cells/L), respectively. The
overall in-hospital mortality rate was 64.3% (18/28) for
the 28 dogs included in this study. Of the nonsurvivors,
only 1 case was euthanized, a dog with acute hepatitis
and liver failure. When survivors and nonsurvivors
were compared, none of the physical parameters
showed significant differences between the 2 groups.
There was no detectable IL-6 or HMGB1 in plasma of
healthy control dogs. Median plasma HMGB1 concen-
trations in nonsurvivors (0.718 mg/L, IQR; 0.300–
1.626 mg/L) were significantly higher than those found
in survivors (0.300 mg/L, IQR; 0.300–0.312mg/L, P 5
0.007). In nonsurvivors, the mean plasma IL-6 concen-
tration (0.126 mg/L, IQR; 0.063–1.348mg/L) was twice
the concentration found in the survivors (0.063 mg/L,
IQR; 0.063–0.289mg/L); however, this difference was
not significantly different between the groups (P 5
0.252). The mean plasma IL-10 concentration was not
statistically different between groups (P 5 0.415). The
ratio of HMGB1 to IL-10 was significantly increased
in the nonsurvivors as compared with survivors
(P 5 0.024), whereas the ratio of IL-6 to IL-10 did not
differ significantly between groups (P 5 0.270) (Table 1
and Figure 1).
In receiver operator characteristic curve analysis with
death as the outcome, the following area under the
curve values were calculated: IL-6 – 0.622 (95% CI,
0.416–0.829); IL-10 – 0.594 (95% CI, 0.361–0.828);
IL-6:IL-10 – 0.628 (95% CI, 0.417–0.838); HMGB1 –
0.794 (95% CI, 0.631–0.958); and HMGB1/IL-10 – 0.761
(95% CI, 0.581–0.941). HMGB1 and HMGB1/IL-10 were
found to be the best discriminator between survivors
and nonsurvivors in this comparative receiver operator
characteristic curve analysis (Figure 2).
Discussion
To the authors’ knowledge this is the 1st report to relate
initial plasma HMGB1 concentrations to prognosis in
dogs with SIRS. Dogs with SIRS and increased plasma
concentration of HMGB1 were associated with worse
outcome regardless of the etiology of SIRS. Similar to
the findings in our study, Wang et al13 found that
human patients who died with sepsis-associated SIRS
had significantly higher HMGB1 concentrations than
survivors.
The prognostic value of measuring HMGB1 may be
due, in part, to its kinetics. After LPS administration in
a murine model of endotoxemia, serum HMGB1 con-
centrations peaked at 16–32 hours, which is later when
compared with other cytokines, including IL-6. Wang
et al13 described HMGB1 as a late mediator of endo-
toxin lethality. In a human cohort study concerning the
kinetics of HMGB1, plasma HMGB1 concentrations re-
mained high in a majority of the septic patients for up
to 1 week after hospitalization.17 The ability to measure
a surrogate marker late in the course of disease may
offer distinct advantages in veterinary medicine be-
cause few veterinary clinical patients are presented to
veterinarians within a short time from the onset of
clinical signs. The results of the present study demon-
strate that a HMGB1 response can be readily detected
Table 1: Selected parameters in survivors and nonsurvivors among 28 dogs with SIRS
Variable Survivors (n 5 10) Nonsurvivors (n 5 18) P-value
T (1C) 38.9 (38.1–40.2) 39.8 (38.0–40.2) 0.79n
PR (beats/min) 145 (124–160) 150 (120–180) 0.68n
RR (breaths/min) 48.0 (32.5–85.0) 63.0 (29.0–90.0) 0.71w
WBC count (109 cells/L) 9.90 (6.65–15.0) 11.9 (1.60–33.1) 0.58n
IL-6 (mg/L) 0.063 (0.063–0.289) 0.126 (0.063–1.348) 0.25w
IL-10 (mg/L) 0.302 (0.286–0.385) 0.307 (0.298–0.446) 0.42w
IL-6/IL-10 0.224 (0.165–0.967) 0.239 (0.204–3.910) 0.27w
HMGB1 (mg/L) 0.300 (0.300–0.312) 0.718 (0.300–1.626) 0.007w
HMGB1/IL-10 1.017 (0.862–1.126) 2.236 (0.972–5.367) 0.024w
Data are presented as the median (interquartile range).
T, body temperature; PR, pulse rate; RR, respiration rate; HMGB1, high-mobility group box 1; SIRS, systemic inflammatory response syndrome.
nStudent’s t-test.
wMann-Whitney U-test.
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in a heterogeneous population of dogs with SIRS. Thus,
HMGB1 has the potential to be an important prognostic
biomarker in dogs with SIRS. We have subsequently
confirmed via Western blotting a clear band around
30 kDa in the serum from septic dog and also in tissues
by using anti-HMGB1 polyclonal antibody (unpub-
lished data). However, this method for HMGB1 detec-
tion is time consuming, and may have further
limitations including possible cross-reaction with light
chains of immunoglobulins as suggested by the other
investigators.17
Interestingly, IL-6 concentrations were not related to
outcome in this study. Our inability to identify a rela-
tionship between IL-6 concentration and outcome could
be related to sampling time issues. In an experimentally
induced canine model of endotoxemia, tumor necrosis
factor-a and IL-1b concentrations peaked within 3
hours to initiate the immune response, then decreased
to normal concentrations within a few hours.24 In both
animal models and human studies, IL-6 increased more
gradually over the 1st hour and began to decrease after
6 hours.25–28 IL-6 measured 6 hours after the initiation
of experimental sepsis has been used to predict mor-
tality.25 However, the transient nature of many pro-
inflammatory cytokines, including IL-6, would make
them less reliable as late biomarkers and this may ex-
plain some of the results of our study. Alternately, the
lack of significant differences in the IL-6 results could
be related to the small sample size because there was a
trend for higher values in the nonsurvivors as com-
pared with survivors.
Figure 1: Plasma cytokine concentration in dogs with SIRS. Increased concentrations of plasma HMGB1 (P 5 0.007) (a) and the ratio
of HMGB1 to IL-10 (P 5 0.024) (d) in the nonsurvivors compared with survivors among 28 dogs with SIRS (bars show means). Plasma
IL-6 (b) and IL-10 (c) levels are not significantly different between groups. HMGB1, high mobility group box 1; SIRS, systemic
inflammatory response syndrome.
Figure 2: Receiver operating characteristic curves comparing
the discriminating capabilities of prognostic markers between
survivors and nonsurvivors.
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In addition to our evaluation of individual cytokines,
we examined ratios of pro- and anti-inflammatory
cytokines for their potential use as biomarkers. The
manifestation of SIRS may be more than the conse-
quence of excessive proinflammatory cytokine produc-
tion. SIRS may also result from a failure or imbalance of
the protective mechanisms against systemic inflamma-
tion, and this was the reason we elected to examine the
ratio of proinflammatory and anti-inflammatory cyto-
kines as possible prognostic surrogate markers.12 To
our knowledge, this is the 1st study to specifically test
the ratio of HMGB1 to IL-10 as a predictor of survival
in dogs. Although plasma IL-10 concentrations alone
were not predictive of survival, we did identify that the
ratio of HMGB1 to IL-10 was significantly increased in
the nonsurvivors as compared with the survivors
(P 5 0.024). However, in this study, the ratio did not
appear to have advantages over the use of HMGB1
alone. The ratio of IL-6 to IL-10 did not differ signifi-
cantly between survivors and nonsurvivors. As with
our IL-6 results, it is possible these results were related
to the timing with regard to sample acquisition.
In conclusion, our data demonstrate a significant in-
crease in plasma HMGB1 in nonsurvivors compared
with survivors in dogs with SIRS and this finding sup-
ports the use of HMGB1 as a prognostic biomarker.
Future studies determining the potential role of using
HMGB1 in the diagnosis of various illnesses, including
the differentiation of sepsis and nonsepsis-associated
SIRS, are warranted.
Footnotes
a DuoSet ELISA Development Kit, R&D Systems, Minneapolis, MN.
b HMGB1 Detection Set, Enzo Life Sciences AG, Lausen, Switzerland.
c VersaMax, Molecular Devices Corp, Sunnyvale, CA.
d Softmax Pro Software, version 5.3, Molecular Devices Corp, Boston, MA.
e SPSS Software, version 15.0, SPSS, Chicago, IL.
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